All News

Data from the phase 3b ALIDHE study may enrich knowledge on ivosidenib plus azacitidine’s safety and efficacy in IDH1-mutated acute myeloid leukemia.

The approval of durvalumab plus FLOT for patients with resectable gastric/GEJ cancer cements itself as a new standard of care in the space.

Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, discussed the top hematologic oncology abstracts from the 2025 ASH Annual Meeting and Exposition.

The addition of zovegalisib to fulvestrant led to rapid declines in PIK3CA and ESR1 ctDNA in the HR-positive/HER2-negative advanced breast cancer group.

Clinicians who are experienced with immunotherapy, like durvalumab, can easily identify and manage AEs associated with treatment for gastric/GEJ cancer.

Numerous clinicians spoke about breaking news, clinical trial updates, and the evolution of standard-of-care treatment throughout 2025.

Based on results from the MATTERHORN study of durvalumab/FLOT in gastric/GEJ cancer, the regimen should be considered a new SOC.

Michelle Riba, MD, discusses the evolution of distress screening in oncology and the move toward a collaborative care model to integrate psychosocial support into clinical practice.

From KRAS inhibitors in metastatic CRC to radioligands and PET imaging agents in prostate cancer, dozens of oncologic approvals were reported in 2025.

Yelena Y. Janjigian, MD, provides the background of the MATTERHORN trial, showcasing the importance of durvalumab plus FLOT in gastric/GEJ cancers.

Daniel C. McFarland, DO, and Charles Kamen, PhD, MPH, discuss the unique challenges that sexual and gender minority groups experience in cancer care.

Moving the needle in cancer research was an important focus for the journal ONCOLOGY in 2025.

Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Kandance P. McGuire, MD, FACS, breaks down what lymphedema is and why it may be detected later.

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

A total of 33% of patients with advanced prostate cancer receiving the combination therapy remained progression-free per PSA after 1 year of treatment.

Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.

How John G. Phillips, MD, MPH, and Tennessee Oncology are aiming to expand radiation oncology access in smaller communities across Tennessee.

C. Ola Landgren, MD, PhD, and Noopur Raje, MD, discussed results from the ADVANCE trial of DKRd in patients with newly diagnosed multiple myeloma.

Results from the DESTINY-Breast05 trial revealed that T-DXd was superior to T-DM1 in these patients with HER2-positive early breast cancer.

Data from the phase 1/2 GO29781 study support the approval of subcutaneous mosunetuzumab in this follicular lymphoma population.

Unadjusted post-recurrence OS was numerically lower with palbociclib plus endocrine therapy vs endocrine therapy alone in the phase 3 PALLAS trial.

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.

Pooled analysis data from the phase 1 JSKN003-101 and phase 1/2 JSKN003-102 trials support the regulatory decision.

“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.